C6461014 - A Phase 2 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants with Previously Untreated Transformed Small Cell Lung Cancer

2025-524686-24-00 · tracked via the Priya Life Science EU tracker

Sponsor

Pfizer Inc.

Sponsor type

Pharmaceutical company

Therapeutic area

Neoplasms

Decision date

29/06/2026

Enrollment target

Sites

France, Italy, Spain

Condition studied

Small Cell Lung Cancer

Investigational medicinal product(s)

CARBOPLATINETOPOSIDEPF-08634404

Eligibility

Age group

65+ years, 18-64 years

Sex

Female, Male

Primary endpoint

Confirmed ORR as assessed by investigator based on RECIST v1.1, AEs as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention.

Endpoint detail

DOR as assessed by investigator based on RECIST v1.1, PFS as assessed by investigator based on RECIST v1.1, OS, Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing., Predose and postdose concentrations of PF-08634404., Incidence of ADA against PF-08634404.

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524686-24-00 on CTIS ↗ ← All trials in the EU